InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
The Alfred Mann Foundation (AMF) today announced the first subject, a U.S. Marine, SSgt James Sides, as a recipient of its highly anticipated IMES System (implantable myoelectric sensor) – an experimental system that holds the promise of being the first minimally invasive, intuitive, multi-channel control system for prosthetics intended for long term use. The IMES System is currently being studied under the Investigational Device Exemption (IDE) regulations of the U.S. Food and Drug Administration (FDA). AMF’s ongoing trial with injured veterans at the Walter Reed National Medical Military Center anticipates subjects intuitively operating three different prosthetic movements simultaneously: opening and closing the hand, rotating the wrist, and moving the thumb. Combining these three movements enables several grasps that are invaluable for performing everyday tasks.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65112-alfred-mann-foundation-u-s-marine-subject-fda-study-for-imes-system
Bone and Joint Center is a center of hip excellence for arthroscopic surgery of sports-related injuries, FAI, hip impingement, ACL, labral tears and also minimally invasive anterior approach total hip replacement.
In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
A devastating invasive pest with no known natural predators threatens recreational areas, forests, and suburban and urban shade trees. Once a tree is infested, it must be removed, which is why the United States Department of Agriculture (USDA) has designated August as Tree Check Month to encourage the public to look for signs of a devastating invasive pest, the Asian longhorned beetle (ALB). The USDA is asking for help spreading the word about how the public can help save trees with a PSA TV spot, radio scripts, and print advertisements.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7277051-usda-august-tree-check-month-asian-longhorned-beetle-invasive-pest-psa/
Syneron Medical Ltd., the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in London, just prior to the opening of the BODY Conference and Exhibition, which took place in London on November 3-4, 2012 and for which Syneron was the main sponsor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58631-body-shaping-by-syneron
A vastly changing landscape would certainly capture one’s attention. The nation’s trees face an immediate threat from the Asian longhorned beetle (ALB), a devastating invasive pest with no natural predators. With up to 70 percent of the U.S. tree canopy at risk of being lost to this pest, the U.S. Department of Agriculture (USDA) is spreading the word about the beetle this summer with a series of TV, radio and print public service announcements (PSAs).
The adult Asian longhorned beetle (ALB) is active throughout the summer months and into the fall. This invasive pest was first discovered in the U.S. in 1996, likely arriving here unknowingly inside wood packing material from Asia. The insect threatens recreational areas, forests, and suburban and urban shade trees. The beetle attacks 12 genera of trees, including birch, maple and elm. It is truly a landscape-altering invasive pest. And all states are at risk.
To view the multimedia release visit:
http://www.multivu.com/players/English/7569951-usda-psa-asian-longhorned-beetle/
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
The Egyptian Ministry of Antiquities is pleased to announce the launch of an egyptian – international Project using non-invasive and non-destructive surveying techniques for the scanning of Egyptian Pyramids under the title “ScanPyramids” project.
Just because a mystery is 4500 years old doesn’t mean it can’t be solved…” This could be the motto of the exceptional scientific mission launched October 25, 2015, under the authority of the Egyptian Ministry of Antiquities, initiated, designed and coordinated by the Faculty of Engineering of Cairo and the French HIP.Institute (Heritage, Innovation and Preservation). Radiographic muons, aka cosmic particles, infrared thermography, photogrammetry, scanner and 3D reconstruction: the most innovative technologies will be used by researchers of international renown and three major universities: the Faculty of Engineering of Cairo University, Université Laval of Quebec and Nagoya University of Japan. Their goal: to probe the heart of the largest pyramids of Egypt, without drilling the slightest opening.
Four millennia after their construction, these ancient giants are far from having yielded their secrets. The first mystery concerns their construction, especially Khufu, the last of the Seven Wonders of the Ancient World still existing: it is still impossible to describe with certainty how this stone monument, the largest ever built by humans, was erected.
The “ScanPyramids” project has already been approved by the permanent committee of the Ministry of Antiquities and has obtained all necessary permissions from concerned authorities. With a base of more than 5 hectares, its original height of almost 150 meters and a mass of 5 million tons, how was it possible to construct such a wonder in only 25 years?
To view the multimedia release go to:
http://www.multivu.com/players/uk/7671551-scanpyramids-project-launch-egyptian/
